FRAXA Clinical Trial Grant

FRAXA Clinical Trial Grant

Status: ACTIVE
Funder: FRAXA Research Foundation Inc
Last Updated: February 08, 2026

Summary

The FRAXA Clinical Trial Grant aims to expedite the development of treatments for Fragile X syndrome. This flexible grant supports clinical research with human subjects, prioritizing trials of disease-modifying agents validated in animal models. Applications are accepted anytime, with no limits on funding structure or amount, although smaller requests may be favored. The foundation focuses on innovative projects that can lead to effective therapies and ultimately, a cure for Fragile X.

Overview

FRAXA ‘s mission is to find specific treatments and ultimately a cure for Fragile X syndrome. We aim to bring practical treatment into current medical practice as quickly as possible; we prioritize projects that have a clear practical application and the results of which will be shared in a timely fashion. FRAXA Clinical Trial Grant FRAXA Clinical Trial Grant applications may be submitted at any time, and budget is flexible. These grants are strictly for clinical research with human subjects who have Fragile X. Flexible in amount, structure, and duration, but may be subject to some negotiation. Emphasis will be placed on clinical trials of potentially disease-modifying agents which have been previously validated in Fragile X animal models, especially in previous FRAXA-funded research. Other types of clinical research will also be considered, such as biomarker studies in Fragile X patients or trials of symptomatic therapies, but this type of research is a lower priority. No limit to the structure of the grant (can fund PI, postdoc, grad student, technician, supplies, etc.) or time-frame (though all grants over one year still need yearly renewal). No limit on the amount, but please remember that applications are evaluated based on relative value, so smaller requests have an advantage! FRAXA's Strategy FRAXA Research Foundation focuses on research that is likely to lead to new and improved treatments — and ultimately a cure — for Fragile X syndrome, with an emphasis on disease-modifying therapeutics based on uan nderstanding of Fragile X disease mechanisms. Every year, we receive proposals from scientists worldwide seeking funding for the most cutting-edge Fragile X research. Our goal has always been to accelerate the pace of research by eliminating “bottlenecks” in this long and complex process. Our funding priorities are determined by the state of the research and the nature of these bottlenecks, so we constantly re-examine these priorities as the field progresses. In FRAXA’s early years, little was known about basic disease mechanisms, so we placed great emphasis on funding basic research to understand the pathophysiology of Fragile X. Research in the Fragile X field was initially the province of molecular biologists and geneticists, so bringing more neuroscientists into the research community was a high priority. These past efforts have been quite successful, generating detailed insights into the basic biology of Fragile X. Fragile X and the normal function of FMRP are both hot topics in neuroscience today. Thus, basic research into Fragile X disease mechanisms can no longer be considered a bottleneck and is now a lower priority for funding. Other past bottlenecks, such as poor antibodies to FMRP and difficulties obtaining animal models, have been resolved by specific resource grants by FRAXA (some continuing to the present). This has enabled an explosion in translational research in Fragile X, leading to many promising therapeutic strategies in the works. However, this also had the net effect of moving the bottleneck further down the road, to the preclinical validation stage of the development process. In response, FRAXA has developed new methods of validating promising drug treatment strategies in a standardized manner, with vastly greater efficiency. We are now less likely to fund academic labs for years on end to test one particular drug strategy — this approach, though appropriate in the past, is too inefficient today. With the bottleneck at the preclinical validation stage of development essentially resolved, the new bottleneck down the road is now clinical trials.

Eligibility

You can learn more about this opportunity by visiting the funder's website. These grants are strictly for clinical research with human subjects who have Fragile X.Flexible in amount, structure, and duration, but may be subject to some negotiation.No limit to structure of grant (can fund PI, postdoc, grad student, technician, supplies, etc.) or time-frame (though all grants over one year still need yearly renewal).No limit on amount.